PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Respiratory syncytial virus infectious disease

Drugs in development · updated 30 October 2026

Respiratory syncytial virus infectious disease: drugs in development

As of 30 October 2026 there are 13 active clinical trials (recruiting or ongoing, phases I–III) on 12 drugs for respiratory syncytial virus infectious disease. 10 are experimental, that is not yet approved in the United States.

13Active trials
10Experimental drugs
2Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
SIM0916III1NCT07402512
ZiresovirII–III1NCT07658534
A01BII2NCT07208461
SCB-1019TI–II2NCT06984094
S-337395II1NCT07214571
SCB-1022I–II1NCT06984094
SCB-1033I–II1NCT06984094
SYH2066II1NCT07881991
ZelicapavirII1NCT07482657
LYB005I1NCT06442241

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
ArexvyII2NCT06597916
RemdesivirVekluryII2NCT06817889

Sorted by most advanced phase and number of active trials.

All 12 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D018357 “Respiratory Syncytial Virus Infections”.

ItalianoFrançaisDeutsch